1. IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis.
- Author
-
Shumei Y, Yi L, Huanyu M, Zhibin L, Wanlin J, Liqun X, and Huan Y
- Subjects
- Adult, Female, Genotype, Humans, Male, Myasthenia Gravis genetics, Polymorphism, Single Nucleotide, Treatment Outcome, Immunosuppressive Agents therapeutic use, Interleukin-2 genetics, Myasthenia Gravis drug therapy, Tacrolimus therapeutic use
- Abstract
Purpose: The IL-2 gene polymorphisms have been reported to be associated with the development of autoimmune disease. However, there are no published studies examining the influence of the IL-2 gene polymorphisms on the response of myasthenia gravis (MG) patients to tacrolimus (Tac). The goal of this study was to investigate the relationship between the polymorphisms of IL-2 and Tac response in MG patients., Methods: Ninety-two MG patients treated with Tac were studied, including 57 Tac-effective patients and 35 Tac-ineffective patients. Then, we selected four single-nucleotide polymorphisms (SNPs: rs2069776, rs2069772, rs2069762, rs2069763) in the IL-2 gene. Next, we analyzed the distribution of genotypes, allelic frequencies of SNPs, and haplotype frequencies among polymorphisms in the two groups of patients., Results: The distribution of the allelic frequency of the rs2069762 variant differed between the Tac-effective and Tac-ineffective patients (P = 0.02). Genotypes G/T and G/G of rs2069762 were differently distributed between the two groups when the wild genotype T/T was assigned as a reference (P < 0.001 for G/T; P = 0.003 for G/G). Patients with the TAGG haplotype tended to be Tac-ineffective (P < 0.001, OR: 0.15, 95% CI: 0.05-0.43)., Conclusion: Myasthenia gravis patients with the rs2069762 variant, rs2069762 G/T and G/G genotype, and TAGG haplotype for IL-2 tended to respond poorly to Tac treatment.
- Published
- 2019
- Full Text
- View/download PDF